ArticleCureus2026
Prevalence and Clinical Characteristics of Patients With Pseudogout and Concomitant Monosodium Urate Crystals.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePseudogout and gout are crystal-induced arthritides caused by calcium pyrophosphate dihydrate (CPPD) and monosodium urate (MSU) crystals. Reported coexistence rates are generally low (<6%), but prior studies mainly evaluated CPPD deposition in gout cohorts. The prevalence and clinical relevance of concomitant MSU crystals in pseudogout remain unclear. We aimed to determine the coexistence rate of CPPD and MSU crystals in patients with pseudogout and compare clinical characteristics and outcomes by coexistence status.
methodsThis single-center retrospective cohort study was conducted at a tertiary emergency medical center in Tokyo. Consecutive patients diagnosed with pseudogout between April 2018 and November 2025 who underwent synovial fluid aspiration were included. CPPD crystals were identified by polarized light microscopy with simultaneous MSU assessment. Patients were classified into pseudogout-only and gout-superimposed groups. Clinical features, treatments, and time to improvement were compared between the two groups.
resultsCPPD crystals were identified in 107 patients: median age, 86 years; interquartile range, 80-90 years; female sex, 79 (74%). Most patients had monoarticular disease, and the knee was most frequently involved in 92 patients (86%). MSU crystals were detected in 17 patients (15.9%), while 90 (84.1%) had pseudogout alone. Except for higher serum uric acid levels in the gout-superimposed group, no significant differences were found between groups in clinical characteristics, treatment, or outcomes. In coexistence cases, CPPD crystals predominated on polarized light microscopy.
conclusionsMSU crystal coexistence was observed in 15.9% of patients with crystal-proven pseudogout, exceeding previously reported rates. Systematic assessment for MSU crystals during synovial fluid microscopy may facilitate recognition of concomitant gout in patients with pseudogout; however, prospective studies are needed to determine whether such identification changes clinical management or improves patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.